Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.4K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

725
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
725
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

440
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
440
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

627
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
627
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

584
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
584

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination Therapy with Bisoprolol and Tissue Protective Molecule ARA 284 Is Cardio-Protective and Improves Survival in Experimental Cancer Cachexia.

Journal of cardiovascular development and disease·2026
Same author

Combined Bisoprolol and Megestrol Acetate Improves Survival and Preserves Cardiac Performance in a Rat Model of Cancer Cachexia.

Journal of cachexia, sarcopenia and muscle·2026
Same author

Spontaneous closure of left ventricular free-wall rupture after acute myocardial infarction: a case report and review of the literature.

Journal of medical case reports·2026
Same author

Effect of heart rate reduction with ivabradine on quality of life in advanced cancer patients.

ESC heart failure·2026
Same author

Combined Nutritional and Exercise Interventions for Cachexia in Chronic Diseases: A Systematic Review and Meta-analysis Limited to Cancer Cachexia.

Progress in rehabilitation medicine·2026
Same author

Prognostic performance of cardiogenic shock 4 proteins prediction model in infarct-related cardiogenic shock.

ESC heart failure·2026

Related Experiment Video

Updated: Mar 18, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

17.3K

Cardiac cachexia: hic et nunc.

Goran Loncar1, Jochen Springer2, Markus Anker3

  • 1Department of Cardiology Clinical Hospital Zvezdara Belgrade Serbia; School of Medicine University of Belgrade Belgrade Serbia.

Journal of Cachexia, Sarcopenia and Muscle
|July 8, 2016
PubMed
Summary
This summary is machine-generated.

Cardiac cachexia (CC), a complex condition in heart failure (HF), presents challenges in definition and treatment. Aerobic exercise is the most effective strategy for combating muscle wasting in HF patients.

Keywords:
CachexiaDiagnosisHeart failurePrevalenceTreatment

More Related Videos

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.8K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.1K

Related Experiment Videos

Last Updated: Mar 18, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

17.3K
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.8K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.1K

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Geriatrics

Background:

  • Cardiac cachexia (CC) is a complex clinical condition associated with advanced heart failure (HF).
  • Current definitions of CC, particularly regarding criteria beyond weight loss, remain debated.
  • The multifactorial pathophysiology of CC necessitates a deeper understanding for effective therapeutic development.

Purpose of the Study:

  • To explore the complex pathophysiology of cardiac cachexia.
  • To identify potential novel therapeutic targets and biomarkers for early detection.
  • To review current and future strategies for managing cachexia, sarcopenia, and wasting disorders in heart failure.

Main Methods:

  • Literature review and synthesis of current research on cardiac cachexia pathophysiology.
  • Analysis of existing diagnostic criteria and their limitations.
  • Evaluation of therapeutic interventions, focusing on exercise and potential pharmacological agents.

Main Results:

  • The pathophysiology of CC is intricate, involving a complex interplay of factors beyond simple weight loss.
  • No single biomarker currently captures the full spectrum of CC.
  • Early identification of body composition changes is crucial for timely intervention.
  • Aerobic exercise training is the most evidence-based intervention to counteract skeletal muscle wasting in HF patients.

Conclusions:

  • Cardiac cachexia is a significant challenge in heart failure management, requiring multifaceted treatment approaches.
  • Further research into biomarkers and pathophysiological pathways is essential for developing targeted therapies.
  • Aerobic exercise is a recommended and effective strategy for mitigating muscle wasting in heart failure.